Stock listing
Arcutis Biotherapeutics, Inc.
Selected listing: ARQT · NASDAQ · USD · US
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT), Health Technology. Latest release Oct 6, 2026: Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award.
- Ticker
- NASDAQ:ARQT
- Asset type
- Stock
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- NASDAQ
- Currency
- USD
About Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. is a public company traded under the ticker ARQT in the American market. Arcutis focuses on developing innovative therapies for dermatological conditions.
Latest news from Arcutis Biotherapeutics, Inc.
Arcutis’ ZORYVE® (roflumilast) Wins 2026 Marie Claire Beauty Award
October 6, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 2, 2026
Simone Biles Partners with Arcutis to Launch the Skin to Believe In Campaign, Raising Awareness of Seborrheic Dermatitis and Eczema, and Inspiring People to Explore Treatment Options
September 28, 2026
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
September 7, 2026
Arcutis Management to Present at the Morgan Stanley 24th Annual Global Healthcare Conference
September 2, 2026
Events
Research Arcutis Biotherapeutics, Inc.
Arcutis Biotherapeutics, Inc. company profile
View the public company page for Arcutis Biotherapeutics, Inc. on 6ix.
Arcutis Biotherapeutics, Inc. news
Read company news and market updates connected to Arcutis Biotherapeutics, Inc..
Arcutis Biotherapeutics, Inc. investor events
Find investor webinars, events, and replay context for Arcutis Biotherapeutics, Inc..